In for the China biotech gold rush, BeiGene eyes monster $800M-plus Hong Kong IPO
Fast on the heels of Ascletis’ record $400 million raise on the Hong Kong stock exchange, BeiGene is proposing its own IPO in the city — to run parallel with its current listing on Nasdaq. And they aren’t thinking small.
The Beijing-based biotech $BGNE is mum about the details, letting slip only that it’s offering 65,600,000 of its ordinary shares — 13 of which would make one American Depositary Share. Given its current stock price, that would amount to a whopping $873 million raise.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
